Shionogi & Co., Ltd.

Shionogi Announces the Conducting of Drug Discovery Competition
FINDS2010 -Drug seeds fostering type-


Osaka, June 1, 2010 –
Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter
“Shionogi”) publicly invites researchers in Japan to enter their innovative ideas in its drug discovery competition,
FINDS (PHarma-INnovation Discovery competition Shionogi).

Shionogi strives constantly to provide medicine of the best possible kind essential for protection of the health of
the people. Based on this policy, it has continuously offered superior medicines to many people. To continue
fulfilling this objective, Shionogi is committed to finding novel drug “seeds” and develop them for practical use.
The FINDS drug discovery competition which started in fiscal 2007 is a newly collaborative industry-academic
initiative in which researchers in Japan with innovative drug seeds can submit ideas that meet Shionogi’s
specified needs and work with the company to develop them into commercially viable drugs. In the past three
years, Shionogi received the many applications from researchers and we started cooperative research programs
for some of them. This fiscal year, Shionogi features the drug discovery base technologies and conducts
FINDS2010 as new framework to find the earlier-stage seeds than ever .
Through FINDS, Shionogi will work to research and develop its drug discovery base technologies of Japanese
origin in order to continue to develop and manufacture new drugs for use around the world.

Competition Overview

1.

Application period: June 1 to June 30, 2010

2.

Number of research fields: New proposals for drug discovery platforms that will lead to next generation
innovative drugs. (
Next generation antibody drugs, next generation nucleic acid drugs, new base
technologies for vaccines, etc.)

3.

Selection method: Two-stage process



Stage 1: Preliminary screening to select about 10-20% of candidates from online applications through
Shionogi website.



Stage 2: In principle, execution of a comprehensive confidentiality agreement followed by submission
of detailed written research plans, and a final selection of about 10 projects.

4.

Selection criteria: Submissions will be assessed and selected on the basis of factors including degree of
correspondence with Shionogi’s needs, originality, practicality, possibility, potential for industrialization
and conflict with existing company projects.
5.

Research budget: 5 million to 10 million yen per project (currently planned)
1

2


It contains the employment expense who is engaged in under exclusive contract.


It is not for scholarship.

Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596